Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis

Research output: Contribution to journalArticlepeer-review

Abstract

Gastric cancer is a frequent human tumor and often a lethal disease. Targeted therapy for gastric carcinomas is far behind vis-à-vis other solid tumors, primarily because of the paucity of cancer-driving mutations that could be efficiently and specifically targeted by current therapy. Thus, there is a need to discover actionable pathways/proteins and new diagnostic and prognostic biomarkers. In this study, we explored the role of the extracellular matrix glycoprotein EMILIN2, Elastin Microfibril Interfacer 2, in a cohort of gastric cancer patients. We discovered that EMILIN2 expression was consistently suppressed in gastric cancer and high expression levels of this glycoprotein were linked to abnormal vascular density. Furthermore, we found that EMILIN2 had a dual effect on gastric carcinoma cells: on one hand, it decreased tumor cell proliferation by triggering apoptosis, and on the other hand, it evoked the production of a number of cytokines involved in angiogenesis and inflammation, such as IL-8. Collectively, our findings posit EMILIN2 as an important onco-regulator exerting pleiotropic effects on the gastric cancer microenvironment.

Original languageEnglish
Article number100029
JournalMatrix Biology Plus
Volume6-7
DOIs
Publication statusPublished - May 2020

Keywords

  • Angiogenesis
  • Extracellular matrix
  • Gastric cancer
  • Inflammation
  • Tumor microenvironment

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry
  • Biophysics
  • Cell Biology
  • Genetics
  • Histology

Fingerprint

Dive into the research topics of 'Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis'. Together they form a unique fingerprint.

Cite this